Real World Evidence Policy: Is Harmonization between Regulatory and HTA a help or a Hindrance?

ISPOR 2024: SESSION 252

NOVEMBER 19, 2024

PANEL

Katharine Cresswell, BSc (Int), MPH

National Institute for Health and Care Excellence, Manchester, LAN, United Kingdom

Niklas Hedberg, MSc

Dental and Pharmaceuticals Benefits Agency (TLV), Stockholm, Sweden

Patrice Verpillat, MD, MPH, PhD

European Medicines Agency (EMA), Amsterdam, Netherlands

Rita Peeters, PhD, MBA

Johnson & Johnson MedTech, Brussels, Belgium



Evolution of RWE policies across HTA and Regulatory organizations

Rita Peeters, Ph.D., MBA


Disclaimer

Views are my own and not that of my employer, Johnson & Johnson Medtech, nor any of the funding partners of the Innovative Health Initiative, or any of its affiliated entities.

This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112135. The JU receives support from the European Union's Horizon Europe research and innovation programme and life science industries represented by COCIR, EFPIA / Vaccines Europe, EuropaBio and MedTech Europe.

In addition, there are financial and/or in-kind contributions from our Swiss and UK partners.

IDERHA is funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.



Real-world data/RWD is information pertaining to health status and health care delivery that is collected routinely from sources other than traditional clinical trials Real-world evidence/RWE is derived from analysis of RWD. www.iderha.org


Real World Data **Study challenges –** what we hear...



Selection bias Confounding Lack of randomization Missing and Incomplete data Data protection

RWE for regulatory and HTA **acceptance** – what we hear...





RWD/RWE **policies**– what we






Global RWD/RWE Regulatory Policy Landscape











	2013-2017	2018	2019	2020	2021	2022	2023
	 FDA, May 2013, DQ/SM FDA, Dec 2016, FW 	 FDA, Jul, DQ FDA, Dec, FW/DQ/SM 			 FDA, Sep, DQ FDA, Oct, DQ FDA, Nov, DQ FDA, Dec, FW 	FDA, Sep, PGFDA, Dec, FW	 FDA, Jan, SM
•					TGA, Nov, FW		
+)			 HC, Mar, DQ/SM HC, Apr, FW 				
				 NMPA, Jan, FW/DQ/SM NMPA, Aug, FW 	 NMPA, Apr, FW/DQ 	 NMPA, Jul, SM NMPA, Aug, PG 	
0				 EMA, Mar, FW EMA, May, FW EMA, Nov, FW EMA, Dec, FW 	 EMA, Oct, DQ/SM 	 EMA, Feb, FW EMA, Sep, DQ EMA, Sep, DQ 	
	 PDMA, Mar 201 DQ/SM PDMA, Jun 2017 DQ 				 PDMA, Mar, FW/DQ PDMA, Mar, FW/SM 		
•:					 MFDS, Jun, FW/DQ/SM 		
Ð						 Swissmedic, Jul, FW 	
3				 TFDA, Jul, FW/DQ/SM 	 TFDA, Jul, PG 		
					 MHRA, Dec, FW/DQ MHRA, Dec, FW/SM 		




https://globalforum.diaglobal.org/issue/may-2023/rwd-rwe-in-2023-regulatory-policy-world-tour/

IMDRF 2023 - Session 2 Real world Evidence. - adapted.

The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies – PubMed https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1236462/full

RWE for regulatory and HTA **acceptance** – what we are looking for...



Similarities

International data

Collaboration

Harmonization?

RWD/RWE what we want **to discuss...**



Harmonization of RWE policy between regulatory and HTA?



What has been harmonized? What hasn't?





What could be harmonized?



Is it harmonization or convergence?